We have located links that may give you full text access.
Percutaneous ethanol sclerotherapy of postoperative lymphoceles.
AJR. American Journal of Roentgenology 1997 August
OBJECTIVE: The purpose of this study was to describe our experience with ethanol sclerotherapy of postoperative lymphoceles.
MATERIALS AND METHODS: We conducted a retrospective review of 32 patients who in a 6-year period underwent percutaneous ethanol sclerotherapy for the management of postoperative lymphoceles. Twenty-three patients had undergone staging lymphadenectomy for malignant tumors, eight patients had undergone renal transplantation, and one patient had undergone vascular surgery. Of the 32 patients in the study group, eight (25%) had undergone previous aspiration or drainage, and three patients (9%) had undergone surgical lymphocelectomy. Patients were treated by percutaneous drainage under fluoroscopic, sonographic, or CT guidance. Sclerotherapy was done with absolute ethanol. Follow-up was conducted by review of clinical charts and imaging studies and by contacting the patient when necessary.
RESULTS: Technical success was achieved in 30 patients (94%), with resolution of lymphocele shown by clinical and imaging findings. Treatment was unsuccessful in two patients (6%), and two patients (6%) had recurrences. Three patients (9%) subsequently underwent surgical treatment of the lymphoceles. Of these three patients, one had a lymphocele recur after surgery, which was then successfully treated with sclerotherapy. The average duration of catheter placement was 19 days. Complications, all minor, included catheter-related infections treated with antibiotics in three patients (9%) and catheter dislodgment that required repeated drainage procedures in two patients (6%). Clinical follow-up averaged 25 months.
CONCLUSION: Percutaneous ethanol sclerotherapy is a safe and effective treatment for postoperative lymphoceles. The technical success rate is high, the recurrence rate is low, and the complication rate is acceptable. Percutaneous sclerotherapy of lymphoceles is a less invasive alternative to surgical treatment.
MATERIALS AND METHODS: We conducted a retrospective review of 32 patients who in a 6-year period underwent percutaneous ethanol sclerotherapy for the management of postoperative lymphoceles. Twenty-three patients had undergone staging lymphadenectomy for malignant tumors, eight patients had undergone renal transplantation, and one patient had undergone vascular surgery. Of the 32 patients in the study group, eight (25%) had undergone previous aspiration or drainage, and three patients (9%) had undergone surgical lymphocelectomy. Patients were treated by percutaneous drainage under fluoroscopic, sonographic, or CT guidance. Sclerotherapy was done with absolute ethanol. Follow-up was conducted by review of clinical charts and imaging studies and by contacting the patient when necessary.
RESULTS: Technical success was achieved in 30 patients (94%), with resolution of lymphocele shown by clinical and imaging findings. Treatment was unsuccessful in two patients (6%), and two patients (6%) had recurrences. Three patients (9%) subsequently underwent surgical treatment of the lymphoceles. Of these three patients, one had a lymphocele recur after surgery, which was then successfully treated with sclerotherapy. The average duration of catheter placement was 19 days. Complications, all minor, included catheter-related infections treated with antibiotics in three patients (9%) and catheter dislodgment that required repeated drainage procedures in two patients (6%). Clinical follow-up averaged 25 months.
CONCLUSION: Percutaneous ethanol sclerotherapy is a safe and effective treatment for postoperative lymphoceles. The technical success rate is high, the recurrence rate is low, and the complication rate is acceptable. Percutaneous sclerotherapy of lymphoceles is a less invasive alternative to surgical treatment.
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app